Targeting topoisomerase IIa in endometrial adenocarcinoma: A combined chromogenic in situ hybridization and immunohistochemistry study based on tissue microarrays

International Journal of Gynecological Cancer

Volumn 16, Issue 3, 2006, Pages 1424-1431

  Tsiambas, E ^a,b,d   Alexopoulou, D ^a   Lambropoulou, S ^a   Gerontopoulos, K ^b   Karakitsos, P ^c   Karameris, A ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b 417 VA Hospital (NIMTS)   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d AG Paraskevi   (Greece)

Author keywords

Chromogenic in situ hybridization; Endometrial adenocarcinoma; Tissue microarrays

Indexed keywords

CHROMOGENIC SUBSTRATE; DEOXYRIBONUCLEIC ACID TOPOISOMERASE IIA; DNA TOPOISOMERASE (ATP HYDROLYSING); PARAFFIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEUPLOIDY; ARTICLE; AUTOANALYZER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL LABELING; CELL NUCLEUS; CHROMOSOME 17; CLINICAL ASSESSMENT; CLINICAL OBSERVATION; COMPUTER PROGRAM; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; STATISTICAL ANALYSIS; TISSUE MICROARRAY; TISSUE SECTION;

ADENOCARCINOMA; AGED; ANTIGENS, NEOPLASM; CHROMOGENIC COMPOUNDS; CHROMOSOMAL INSTABILITY; CHROMOSOMES, HUMAN, PAIR 17; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PROTEIN ARRAY ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 33745099247     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00562.x     Document Type: Article

References (29)

1. Silverberg SG Kurman RJ Nogales F Mutter GL Kubik-Huch RA Tavassoli FA. Epithelial tumours and related lesions. In : Tavassoli FA Devilee P, eds. Pathology and genetics: tumours of the breast and female genital organs (WHO). Lyon, France : IARC Press, 2003 : 221 32.
2. Ciricano FD Robboy SJ Dodge RK Bentley RC Krigman HR Synan IS. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000 77 : 55 65.
3. Sherman ME Bur ME Kurman RJ. P53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995 26 : 1268 74.
4. Mutter GL. PTEN, a protean tumour suppressor. Am J Pathol 2001 158 : 1895 8.
5. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001 61 : 1 13.
6. Roman JMV Martinez LAR. Comparative assays for the HER2/neu oncogene status in breast cancer. Arch Pathol Lab Med 2004 128 : 627 33.
7. Watters AD Going JJ Cooke TG Barlett JM. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast adenocarcinoma. Breast Cancer Res Treat 2003 77 : 109 14.
8. Shin IM Zhou W Goodman SN Lengauer C Kinzler KW Vogelstein B. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res 2001 61 : 818 22.
9. Moskovitz AH Linford NJ Brentnall TA et al. Chromosomal instability in pancreatic ductal cells from patients with chronic pancreatitis and pancreatic adenocarcinoma. Genes Chromosomes Cancer 2003 37 : 201 6.
10. Brustmann H. Immunohistochemical detection of human telomerase reverse transcriptase (h-TERT), topoisomerase IIa expression and apoptosis in endometrial adenocarcinoma and atypical hyperplasia. Int J Gynecol Pathol 2005 24 : 192.
11. Bildrici K Tel N Ozalp SS Yalcin OT Yilmaz V. Prognostic significance of DNA topoisomerase IIa (Ki-S1) immunoexpression in endometrial carcinoma. Eur J Gynaecol Oncol 2002 23 : 540 4.
12. Adlard JW Dodwell DJ. Optimum anthracycline-based chemotherapy for early breast cancer. Lancet Oncol 2001 2 : 469 74.
13. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomized trial. Lancet 2002 360 : 505 15.
14. Thigpen TJ Aghajanian CA Alberts DS et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 2005 96 : 10 7.
15. Muggia FM Blessing JA Sorosky J Reid GC. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2002 20 : 2360 4.
16. Campos SM Matulonis UA Penson RT et al. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumours. Gynecol Oncol 2003 9 : 14 21.
17. Gil J Haishan WU Wang BY. Image analysis and morphometry in the diagnosis of breast cancer. Microsc Res Tech 2002 59 : 109 18.
18. Scorilas A Fotiou S Tsiambas E et al. Determination of cathepsin B expression may offer additional information for ovarian cancer patients. Biol Chem 2002 383 : 1297 303.
19. Mueller R Parkes R Andrulis I O'Malley F. Amplification of Topo2A gene does not predict high levels of topoisomerase IIa protein in human breast tumour samples. Genes Chromosomes Cancer 2004 39 : 288 97.
20. Tsiambas E Stamatelopoulos A Vilaras G Thanopoulou E Karameris A. Morphometric study of immunohistochemical expression of topoisomerase IIa and p16 correlating with molecular detection of chromosome 17 and 9 instability in pancreatic adenocarcinoma using Tissue Microarrays application. J Clin Oncol, 2005 23 : 332.
21. Kounelis S Kapranos N Malamos N Kouri-Bairaktari E. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry. Anticancer Res 2005 25 : 939 46.
22. Stoecklein NA Luebke AM Erbesdobler A et al. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol, 2005 22 : 4737 45.
23. Peiro G Mayr D Hillemanns P Lohrs U Diebold J. Analysis of HER2/neu amplification in endometrial adenocarcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization HER2/neu, p53 and Ki-67 protein expression and outcome. Mod Pathol 2004 17 : 227 37.
24. Koshiyama M Fujii H Kinezaki M Morita Y Nanno H Yoshida M. Immunohistochemical expression of topoisomerase IIa and multidrug resistance-associated protein, plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Anticancer Res 2001 21 : 2925 32.
25. Mano MS Awada A Di Leo A et al. Rates of Topo IIa and HER2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol 2004 92 : 887 95.
26. Hendriks Y Franken P Dierssen JW et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol 2003 162 : 469 77.
27. Hoos A Urist MJ Stojadinovic A et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001 158 : 1245 51.
28. Rubin M Dunn R Strawderman M. Tissue microarray sampling strategy for prostrate cancer biomarkers analysis. Am J Surg Pathol 2002 26 : 312 9.
29. Sanderson SO Sebo TJ Murphy LM Neumann R Slezak J Cheville JC. An analysis of the p63/alpha-methylacyl coenzyme. A racemase immunohistochemical cocktail stain in prostrate needle biopsy specimens and tissue microarrays. Am J Clin Pathol 2004 121 : 220 5.